Developing CAR T Cell Therapies With Sefia™ Cell Therapy Manufacturing Platform

CAR T cell therapies have evolved rapidly since their early use in hematologic malignancies, with advances such as dual-targeting constructs and CRISPR-enabled engineering expanding their therapeutic potential. Yet, the path to broader patient access remains constrained by labor-intensive, multistep manufacturing processes that are difficult to scale.

An integrated approach to automation is emerging as a solution, combining closed-system T cell isolation, activation, transduction, and expansion into a streamlined workflow. Flexible, modular platforms with digital controls enable consistent processing of both fresh and frozen apheresis inputs, while supporting diverse reagents and protocols. Early results demonstrate the ability to reliably generate functional CAR T cells with improved efficiency and reproducibility—key steps toward making these therapies more accessible.

Gain insight into how automation is reshaping manufacturing at scale.